Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03735251 |
| Other study ID # |
ELITISM |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
July 10, 2014 |
| Est. completion date |
August 10, 2014 |
Study information
| Verified date |
July 2014 |
| Source |
Shanghai 10th People's Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
This study is one of the largest ongoing prospective population studies to evaluate target
organ damages (TODs) and Left Ventricular Diastoic Dysfunction in the community-dwelling
elderly Chinese, which is authorised and funded by the Shanghai municipal government.This
study was approved by the Shanghai Tenth People's Hospital Institutional Review Board and was
conducted under financial support from the Shanghai municipal government (grant ID:
2013ZYJB0902 and 15GWZK1002). The preliminary sample size is expected to be 3000-4000
participants.
Description:
The Northern Shanghai Study is an ongoing prospective community-based study. After enrolment,
clinical examination,anthropometric measurement and a questionnaire will be administered to
each participant at baseline and patients will be followed up every six months. Our tests and
examinations include: blood/urine sample and biochemical measurements, office blood pressure
recording, carotid ultrasonograph, echocardiograph, pulse wave velocity, pulse wave analysis,
4-limb blood pressure recording, body mass index, etc. Baseline measurement will also include
the assessments on target organ damages(TODs) and the conventional CV risk factors. In the
follow-up, the incidence of CV events and mortality will be recorded. The Northern Shanghai
Risk Score will be calculated, with considerations on CV risk factors and TODs.